Insulinoma Clinical Trial
Official title:
The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma
The small insulinoma can not be detected by the CT or MRI. We use 68Ga-NOTA-exendin-4 positron emission tomography/computed tomography (PET/CT) to detect the insulinoma for the patient diagnosed with endogenous hyperinsulinemic hypoglycaemia. And the diagnostic value will be performed. A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.
The glucagon-like peptide-1 receptor (GLP-1R) is an emerging target due to its high expression in benign insulinomas. 68Ga-NOTA-exendin-4 is an optimal probe targeting GLP-1R. The clinical use of 68Ga-NOTA-exendin-4 PET/CT in detecting insulinomas will be evaluated. And the comparation between PET diagnostic value and CT / MRI will be done. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02021604 -
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
|
Phase 1 | |
| Withdrawn |
NCT02108782 -
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT05034783 -
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
|
Early Phase 1 | |
| Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
| Completed |
NCT00937079 -
Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
|
Phase 1 | |
| Recruiting |
NCT04185350 -
Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
|
Early Phase 1 | |
| Recruiting |
NCT00001276 -
Diagnosing and Treating Low Blood Sugar Levels
|
||
| Active, not recruiting |
NCT02121366 -
EUS-guided Ethanol Ablation of an Insulinoma
|
N/A | |
| Terminated |
NCT00084461 -
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00131911 -
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00005910 -
Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
|
N/A | |
| Recruiting |
NCT03583528 -
DOTATOC PET/CT for Imaging NET Patients
|
||
| Withdrawn |
NCT04915144 -
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
|
Phase 2 | |
| Recruiting |
NCT05523778 -
A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct
|
N/A | |
| Recruiting |
NCT02560376 -
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
|
Phase 0 | |
| Completed |
NCT01525082 -
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00655655 -
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00075439 -
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
| Terminated |
NCT04452396 -
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
|
N/A | |
| Active, not recruiting |
NCT01824875 -
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 2 |